Clinical trial
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer…
NCT00305838 · Mount Vernon Cancer Centre at Mount Vernon Hospital, Other · Unknown status
Key facts
| NCT number | NCT00305838 |
|---|---|
| Title | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen |
| Official title | Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen |
| Lead sponsor | Mount Vernon Cancer Centre at Mount Vernon Hospital, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug, Other |
| Interventions | tamoxifen citrate, diagnostic laboratory biomarker analysis |
| Enrollment | 200 |
| Start date | Mar 1, 2004 |
| Primary completion | Dec 1, 2008 |
| First posted | Mar 22, 2006 |
| Last update posted | Aug 12, 2013 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: